The role of endothelial dysfunction in the pathogenesis of neuropsychiatric systemic lupus erythematosus

Lupus

Volumn 19, Issue 7, 2010, Pages 797-802

  Davey, R ^a   Bamford, J ^b   Emery, P ^b  

^a British Association for Immediate Care   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Endothelial dysfunction; Neuropsychiatric; Stroke; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COGNITIVE DEFECT; CONFUSION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOPPLER ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; EPISODIC TENSION HEADACHE; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE CEREBRAL ARTERY; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROPATHY; OPTIC NERVE DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SEIZURE; STROKE; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK;

ADULT; CASE-CONTROL STUDIES; COGNITION DISORDERS; ENDOTHELIUM, VASCULAR; FEMALE; HEADACHE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 77952932180     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309359780     Document Type: Article

References (43)

1. Swaak AJ, Nossent JC, Bronsveld W., et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989 ; 48: 447-454.
2. Ward MM Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 338-346.
3. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001 ; 57: 496-500. (Pubitemid 32757599)
4. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002 ; 58: 1214-1220.
5. Hanly JG, McCurdy G., Fougere L., Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004 ; 31: 2156-2162.
6. Hanly JG ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004 ; 13: 861-864.
7. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 ; 42: 599-608.
8. Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993 ; 22: 335-349.
9. Gonzalez-Crespo MR, Blanco FJ, Ramos A., et al. Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br J Rheumatol 1995 ; 34: 1055-1060.
10. Shen YY, Kao CH, Ho YJ, Lee JK Regional cerebral blood flow in patients with systemic lupus erythematosus. J Neuroimaging 1999 ; 9: 160-164.
11. Johnson RT, Richardson EP The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968 ; 47: 337-369.
12. Ellis SG, Verity MA Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979 ; 8: 212-221.
13. Devinsky O., Petito CK, Alonso DR Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988 ; 23: 380-384.
14. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992 ; 19: 732-741.
15. Mitsias P., Levine SR Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994 ; 44: 385-393.
16. Sanna G., Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003 ; 30: 985-992.
17. Bruce IN, Gladman DD, Urowitz MB Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000 ; 26: 257-278.
18. Esdaile JM, Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001 ; 44: 2331-2337.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 ; 340: 115-126.
20. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay MA Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004 ; 51: 447-450.
21. Filer AD, Gardner-Medwin JM, Thambyrajah J., et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003 ; 62: 162-167.
22. Lima DS, Sato EI, Lima VC, Miranda F. Jr, Hatta FH Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002 ; 29: 292-297.
23. Somers EC, Marder W., Kaplan MJ, Brook RD, McCune WJ Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. Ann NY Acad Sci 2005 ; 1051: 271-280.
24. El-Magadmi M., Bodill H., Ahmad Y., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004 ; 110: 399-404.
25. Csepany T., Valikovics A., Fulesdi B., Kiss E., Szegedi G., Csiba L. Cerebral systemic lupus erythematosus. Lancet 1994 ; 343: 1103.
26. Grunwald F., Schomburg A., Badali A., Ruhlmann J., Pavics L., Biersack HJ 18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus. Eur J Nucl Med 1995 ; 22: 1073-1077.
27. Koseda-Dragan M., Lass P., Hebanowski M. Cerebral blood flow in systemic lupus erythematosus. Lupus 2001 ; 10: 519-520.
28. Lass P., Koseda M., Romanowicz G., et al. Cerebral blood flow assessed by brain SPECT with 99mTc-HMPAO utilising the acetazolamide test in systemic lupus erythematosus. Nucl Med Rev Cent East Eur 1998 ; 1: 20-24.
29. Markus HS Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004 ; 75: 353-361.
30. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277.
31. Randolph C., Tierney MC, Mohr E., Chase TN The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998 ; 20: 310-319.
32. Wilson WA, Gharavi AE, Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999 ; 42: 1309-1311.
33. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
34. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996 ; 39: 363-369.
35. Landis JR, Koch GG The measurement of observer agreement for categorical data. Biometrics 1977 ; 33: 159-174.
36. Meroni PL, Tincani A., Sepp N., et al. Endothelium and the brain in CNS lupus. Lupus 2003 ; 12: 919-928.
37. Markus H., Cullinane M. Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. Brain 2001 ; 124: 457-467.
38. Molina C., Sabin JA, Montaner J., Rovira A., Abilleira S., Codina A. Impaired cerebrovascular reactivity as a risk marker for first-ever lacunar infarction: a case-control study. Stroke 1999 ; 30: 2296-2301.
39. Valikovics A., Olah L., Fulesdi B., et al. Cerebrovascular reactivity measured by transcranial Doppler in migraine. Headache 1996 ; 36: 323-328.
40. Dora B., Balkan S., Tercan E. Normalization of high interictal cerebrovascular reactivity in migraine without aura by treatment with flunarizine. Headache 2003 ; 43: 464-469.
41. Lauritzen M., Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984 ; 107: 447-461. (Pubitemid 14108830)
42. Schurks M., Rist P., Bigal ME, Buring J., Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. Brit Med J 2009 ; 339: 3914.
43. Mitsikostas DD, Sfikakis PP, Goadsby PJ A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004 ; 127: 1200-1209.